Clinical trials: Thromboprophylaxis
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral)
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
Endothermal heat-induced thrombosis (EHIT) is a thrombotic complication specific to endovenous thermal ablation of the great saphenous vein (GSV), for which no prophylactic regimen is standardized.
- Conditions
- Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
- Trial name
- NCT07699796
- Testing
- Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 564 people
- Sponsor
- Heart, Artery, and Vein Center of Fresno
Thromboembolism
Thromboprophylaxis and Bariatric Surgery
This trial is an assessment of the efficacy of three thromboprophylaxis regimens in two types of bariatric surgery. gastric banding and gastric bypass on anti-Xa activity levels The study includes two groups of 150 patients…
- Trial name
- NCT00444652
- Testing
- Enoxaparin
- Where
- 10 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Gynecologic Neoplasms, Venous Thromboembolism
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies.
- Conditions
- Gynecologic Neoplasms, Venous Thromboembolism, Low Molecular Weight Heparin, Argatroban
- Trial name
- NCT02935530
- Testing
- s-LMWH, LMWH, Argatroban
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Huazhong University of Science and Technology
Multiple Myeloma, Total Knee Replacement
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis.
- Trial name
- ProApix (NCT06474182)
- Testing
- Blood sampling, Apixaban
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT). The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases…
- Conditions
- Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy, Postpartum
- Trial name
- POSTPART AS5-2 (NCT07342127)
- Testing
- Retrospective collection of health data, Phone call to every participant
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage I
- Trial name
- RithMM (NCT03428373)
- Testing
- Rivaroxaban, ASA
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Postpartum, DVT Prophylaxis
Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis
The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE.
- Trial name
- NCT07716332
- Testing
- Apixaban, Enoxaparin
- Volunteers
- 150 people
- Sponsor
- Ron Beloosesky MD
Traumatic Intracranial Haemorrhage
OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)
Victims of trauma with severe head injury who have bled into their brains are at high risk of developing blood clots in their legs. These blood clots can break off and travel through the bloodstream to the lungs causing death.
- Trial name
- OPTTTICH (NCT01589393)
- Testing
- Enoxaparin
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- McMaster University
Pregnancy
Evaluation of the LMWH Thromboprophylaxis in Pregnancy
The project aims to clarify the effect of the thromboprophylactic LMWH dose on coagulation in pregnant women just before birth, at the period of maximal physiological hypercoagulable state and with high risk of thromboembolism…
- Trial name
- NCT01394107
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- Charles University, Czech Republic
Deep Vein Thrombosis, Pulmonary Embolism
Evaluation of Thromboprophylaxis Appropriateness in Hospitalized Medical Patients
Considering observational studies that suggested a relationship between acutely ill medical patients and venous thromboembolism (VTE), interventional studies with anticoagulant medications indicated a marked decline in VTE during…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboses
- Trial name
- NCT05449808
- Where
- Iraq
- Volunteers
- 320 people
- Sponsor
- Al-Esraa University College
Covid19
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
The purpose of this study is to determine whether a higher dose of low molecular weight heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin 40 mg o.d.) in reducing thromboembolic events in…
- Trial name
- X-Covid 19 (NCT04366960)
- Testing
- Enoxaparin
- Where
- Italy
- Volunteers
- 189 people
- Sponsor
- Niguarda Hospital
Embolism
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
Acutely ill immobilized patients are at a high risk for thromboembolic events including deep venous thrombosis or pulmonary embolism.
- Trial name
- NCT00311753
- Testing
- Certoparin, Heparin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 342 people
- Sponsor
- Novartis Pharmaceuticals
Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Purpose of the Pilot Trial: To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated…
- Conditions
- Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis, Cancer
- Trial name
- TRIM-Line (NCT03506815)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Ottawa Hospital Research Institute
Acute Deep Vein Thrombosis
Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients
To collect postmarketing data about Fragmin safety and efficacy in the treatment of deep vein thrombosis with or without pulmonary embolism in cancer patients.
- Trial name
- NCT00480636
- Testing
- Fragmin (dalteparin sodium )
- Volunteers
- 102 people
- Sponsor
- Pfizer
Medical Patient, Thrombocytopenia
Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
Fondaparinux is a parenteral anticoagulant drug approved for the prophylaxis of venous thromboembolism in high risk medical patients.
- Trial name
- FAITH (NCT01727401)
- Testing
- Fondaparinux
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- G. d'Annunzio University
Obesity
Venous Thromboprophylaxis in Bariatric Surgery
The main aim of this study is to compare the influence of total body-weight (TBW), lean body-weight (LBW), ideal body-weight (IBW) or Body Mass Index (BMI) on peak anti-Xa levels at steady-state in bariatric surgery (BS) morbidly…
- Trial name
- OBSUD (NCT03218514)
- Testing
- Dalteparin
- Volunteers
- 118 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Venous Thromboembolism (VTE)
Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).
Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary…
- Trial name
- NCT06628778
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 802 people
- Sponsor
- Johns Hopkins All Children's Hospital
COVID-19
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Patients with moderate to severe COVID-19 present a very high risk of thromboembolic disease.This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban compared with standard of care with…
- Trial name
- COVID-PREVENT (NCT04416048)
- Testing
- Rivaroxaban, Standard Of Care (SOC)
- Where
- 24 sites in Germany
- Volunteers
- 111 people
- Sponsor
- Charite University, Berlin, Germany
Venous Thromboembolism
Electronic Alert System for Improving Thromboprophylaxis in Hospitalized Medical Patients
The investigators aim to investigate whether a computer-based alert system in the electronic patient chart and order entry system using the Geneva Risk Score as clinical decision support tool to estimate the risk of venous…
- Trial name
- NCT03124017
- Testing
- Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
- Where
- Switzerland
- Volunteers
- 1,756 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Venothromboembolism
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses.
- Trial name
- VTE-AI RCT (NCT06939803)
- Testing
- Risk model-driven CDS
- Where
- United States
- Volunteers
- 2,236 people
- Sponsor
- Vanderbilt University Medical Center